Home >> Pharmaceuticals >> Food & Beverage >>

Yungjin Pharm. Co., Ltd. - Product Pipeline Review - 2015

Published: Aug-2015 | Format: PDF | Global Markets Direct | Number of pages: 42 | Code: MRS - 35135

Yungjin Pharm. Co., Ltd. - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘Yungjin Pharm. Co., Ltd. - Product Pipeline Review - 2015’, provides an overview of the Yungjin Pharm. Co., Ltd.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Yungjin Pharm. Co., Ltd.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Yungjin Pharm. Co., Ltd. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Yungjin Pharm. Co., Ltd.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Yungjin Pharm. Co., Ltd.’s pipeline products

Reasons to buy

- Evaluate Yungjin Pharm. Co., Ltd.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Yungjin Pharm. Co., Ltd. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Yungjin Pharm. Co., Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Yungjin Pharm. Co., Ltd. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Yungjin Pharm. Co., Ltd.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Yungjin Pharm. Co., Ltd. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Yungjin Pharm. Co., Ltd. Snapshot 6
Yungjin Pharm. Co., Ltd. Overview 6
Key Information 6
Key Facts 6
Yungjin Pharm. Co., Ltd. - Research and Development Overview 7
Key Therapeutic Areas 7
Yungjin Pharm. Co., Ltd. - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Combination Treatment Modalities 12
Pipeline Products - Partnered Products 13
Partnered Products/Combination Treatment Modalities 14
Yungjin Pharm. Co., Ltd. - Pipeline Products Glance 15
Yungjin Pharm. Co., Ltd. - Late Stage Pipeline Products 15
Pre-Registration Products/Combination Treatment Modalities 15
Phase III Products/Combination Treatment Modalities 16
Yungjin Pharm. Co., Ltd. - Clinical Stage Pipeline Products 17
Phase II Products/Combination Treatment Modalities 17
Phase I Products/Combination Treatment Modalities 18
Yungjin Pharm. Co., Ltd. - Early Stage Pipeline Products 19
Preclinical Products/Combination Treatment Modalities 19
Discovery Products/Combination Treatment Modalities 20
Yungjin Pharm. Co., Ltd. - Drug Profiles 21
KTG-001 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
(acetaminophen + tramadol hydrochloride) SR 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
YPL-001 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
YBH-1603 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
YNP-1707 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
YOB-1604 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
ceftaroline fosamil 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
YAR-1502 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
YHT-1808 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
YLS-1501 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
YPU-1705 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
YRA-1909 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
YGD-1710 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
YPE-1706 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Yungjin Pharm. Co., Ltd. - Pipeline Analysis 35
Yungjin Pharm. Co., Ltd. - Pipeline Products by Target 35
Yungjin Pharm. Co., Ltd. - Pipeline Products by Route of Administration 36
Yungjin Pharm. Co., Ltd. - Pipeline Products by Molecule Type 37
Yungjin Pharm. Co., Ltd. - Pipeline Products by Mechanism of Action 38
Yungjin Pharm. Co., Ltd. - Dormant Projects 39
Yungjin Pharm. Co., Ltd. - Locations And Subsidiaries 40
Head Office 40
Appendix 41
Methodology 41
Coverage 41
Secondary Research 41
Primary Research 41
Expert Panel Validation 41
Contact Us 41
Disclaimer 42

List of Tables
Yungjin Pharm. Co., Ltd., Key Information 6
Yungjin Pharm. Co., Ltd., Key Facts 6
Yungjin Pharm. Co., Ltd. - Pipeline by Indication, 2015 9
Yungjin Pharm. Co., Ltd. - Pipeline by Stage of Development, 2015 10
Yungjin Pharm. Co., Ltd. - Monotherapy Products in Pipeline, 2015 11
Yungjin Pharm. Co., Ltd. - Combination Treatment Modalities in Pipeline, 2015 12
Yungjin Pharm. Co., Ltd. - Partnered Products in Pipeline, 2015 13
Yungjin Pharm. Co., Ltd. - Partnered Products/ Combination Treatment Modalities, 2015 14
Yungjin Pharm. Co., Ltd. - Pre-Registration, 2015 15
Yungjin Pharm. Co., Ltd. - Phase III, 2015 16
Yungjin Pharm. Co., Ltd. - Phase II, 2015 17
Yungjin Pharm. Co., Ltd. - Phase I, 2015 18
Yungjin Pharm. Co., Ltd. - Preclinical, 2015 19
Yungjin Pharm. Co., Ltd. - Discovery, 2015 20
Yungjin Pharm. Co., Ltd. - Pipeline by Target, 2015 35
Yungjin Pharm. Co., Ltd. - Pipeline by Route of Administration, 2015 36
Yungjin Pharm. Co., Ltd. - Pipeline by Molecule Type, 2015 37
Yungjin Pharm. Co., Ltd. - Pipeline Products by Mechanism of Action, 2015 38
Yungjin Pharm. Co., Ltd. - Dormant Developmental Projects,2015 39

List of Figures
Yungjin Pharm. Co., Ltd. - Pipeline by Top 10 Indication, 2015 8
Yungjin Pharm. Co., Ltd. - Pipeline by Stage of Development, 2015 10
Yungjin Pharm. Co., Ltd. - Monotherapy Products in Pipeline, 2015 11
Yungjin Pharm. Co., Ltd. - Pipeline by Top 10 Target, 2015 35
Yungjin Pharm. Co., Ltd. - Pipeline by Top 10 Route of Administration, 2015 36
Yungjin Pharm. Co., Ltd. - Pipeline by Top 10 Molecule Type, 2015 37
Yungjin Pharm. Co., Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2015 38

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)1500 View Pricing